GlobalRPh Renal Dosing Masterv6.6
Source review / handoff

Oseltamivir

One or two intact local summaries. No averaged regimen, patient-specific dose or automatic source preference.

Return to full drug recordAll source differencesRead selected sourcesHow to use this review

Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.

Share or print this source review

1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.

Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.

Clinical context remains essential

Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.

Check source scope before reading a dose

UCSF - oseltamivir treatment versus prevention

Product / population
Adults; source-specific institutional guidance. Match route, indication and renal replacement modality.
Renal method
CrCl in mL/min where specified; no equation inferred.
Source revision
Revision date not stated in the reviewed page.
Retrieved
2026-09-05
Local review status
Locally included source-specific summary. Regimen differences are not automatically resolved.

Documented differences and cautions on this drug

All record notes are retained here, including notes about sources not selected in this review.

CAPD threshold differs between the mirror and official label

The mirror CAPD row prints below 10 mL/min; the dated official label includes 10 or below. Treatment and prophylaxis schedules also differ.

What to reconcile: Preserve the discrepancy; use the exact population, modality and indication. Do not transfer CAPD guidance to automated PD or CRRT.

Source-specific interpretation; independent clinician adjudication pending.

Open this note and its source references
Professional

UCSF - oseltamivir treatment versus prevention

Open original reference

UCSF Infectious Diseases Management Program · Adults; source-specific institutional guidance. Match route, indication and renal replacement modality.

Renal method: CrCl in mL/min where specified; no equation inferred.
Source date: Revision date not stated in the reviewed page.
Retrieved: 2026-09-05

Locally included source-specific summary. Regimen differences are not automatically resolved.

Dosing / renal protocol and limits

Limits that apply to these rows

Choose duration separately. No non-dialysis regimen below the displayed range is inferred.

Influenza treatment - oral
CrCl, mL/minSource-specific dose / instruction
>6075 mg twice daily
31-6030 mg twice daily
10-3030 mg daily
Influenza prevention - oral
CrCl, mL/minSource-specific dose / instruction
>6075 mg daily
31-6030 mg daily
10-3030 mg every other day
Dialysis guidance - separate source-specific schedules
Oseltamivir dialysis
Dialysis setting / indicationSource-specific schedule
IHD treatment30 mg initially and after HD
IHD prevention30 mg once weekly
Continuous HD treatment75 mg twice daily
Continuous HD prevention30 mg daily
Read the retained text before reformatting

CrCl >60 / 31-60 / 10-30 mL/min: influenza treatment uses 75 mg orally twice daily / 30 mg twice daily / 30 mg daily. Prevention uses 75 mg daily / 30 mg daily / 30 mg every other day.

Intermittent-HD treatment: 30 mg initially and after HD; prevention: 30 mg once weekly. Continuous-HD treatment: 75 mg twice daily; prevention: 30 mg daily. Course duration is selected separately. No non-dialysis dose below the listed clearance range is inferred.

RDM30-043-oseltamivir-1 · Source locator: UCSF - oseltamivir treatment versus prevention; renal/dosing sections and stated qualifiers

Source identity and provenance
Source
https://idmp.ucsf.edu/content/oseltamivir
Retrieved
2026-09-05
Renal-function method
CrCl in mL/min where specified; no equation inferred.
Source date/version
Revision date not stated in the reviewed page.
Hash meaning
Locally authored summary text; not original SPL, HTML or PDF bytes
Local summary SHA-256
0ecf61f68c61d350792212142104e18aa41970d9baa2b2485818b44235505ede

Document the clinical decision separately

This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.

GlobalRPh v6.6 | RDM66-DIRECT-PHP-20260911 | Local library date 2026-09-11. Selected-card identity does not imply clinical verification.

Pinned reference: https://globalrph.com/blogCalcs/renal-dosing-master/compare.php?id=oseltamivir&s1=RDM30-043-oseltamivir&h1=a65d4c3f901e4db1787e3918bc331c834af65701d5ce8ef34a285c6f49aed706